SI2272868T1 - Combination therapy for B cell disorders - Google Patents

Combination therapy for B cell disorders

Info

Publication number
SI2272868T1
SI2272868T1 SI200432245T SI200432245T SI2272868T1 SI 2272868 T1 SI2272868 T1 SI 2272868T1 SI 200432245 T SI200432245 T SI 200432245T SI 200432245 T SI200432245 T SI 200432245T SI 2272868 T1 SI2272868 T1 SI 2272868T1
Authority
SI
Slovenia
Prior art keywords
combination therapy
cell disorders
disorders
cell
therapy
Prior art date
Application number
SI200432245T
Other languages
Slovenian (sl)
Inventor
Andrew Chan
Qian Gong
Flavius Martin
Original Assignee
Genentech, Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., filed Critical Genentech, Inc.,
Priority claimed from EP10009416.8A external-priority patent/EP2272868B1/en
Publication of SI2272868T1 publication Critical patent/SI2272868T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
SI200432245T 2003-06-05 2004-06-04 Combination therapy for B cell disorders SI2272868T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47648103P 2003-06-05 2003-06-05
US47641403P 2003-06-05 2003-06-05
US47653103P 2003-06-06 2003-06-06
EP10009416.8A EP2272868B1 (en) 2003-06-05 2004-06-04 Combination therapy for B cell disorders

Publications (1)

Publication Number Publication Date
SI2272868T1 true SI2272868T1 (en) 2015-07-31

Family

ID=37003283

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200432245T SI2272868T1 (en) 2003-06-05 2004-06-04 Combination therapy for B cell disorders
SI200432241T SI1631313T1 (en) 2003-06-05 2004-06-04 Combination therapy for b cell disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200432241T SI1631313T1 (en) 2003-06-05 2004-06-04 Combination therapy for b cell disorders

Country Status (3)

Country Link
CN (1) CN1835972A (en)
DK (1) DK2272868T3 (en)
SI (2) SI2272868T1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101851278B (en) * 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B cell activating factor antagonist as well as preparation method and application thereof
JP6271254B2 (en) * 2011-02-28 2018-01-31 ジェネンテック， インコーポレイテッド Methods for predicting biological markers and responses to B cell antagonists
MX2013011385A (en) * 2011-04-01 2014-03-13 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof.
CN103936833B (en) * 2014-04-18 2016-02-10 天津大学 BLyS antagonistic peptide, containing the plasmid of TC-Fc antigen-4 fusion protein gene and TC-Fc fusion rotein
CN113136365A (en) * 2021-04-29 2021-07-20 中山大学附属口腔医院 Reagent for inducing high-efficiency amplification of regulatory B cells based on histone deacetylase inhibitory activity and application thereof

Also Published As

Publication number Publication date
CN1835972A (en) 2006-09-20
SI1631313T1 (en) 2015-06-30
DK2272868T3 (en) 2015-06-15

Similar Documents

Publication Publication Date Title
PL1631313T3 (en) Combination therapy for b cell disorders
AU2003259152A8 (en) Cell therapy for regeneration
AU2003282679A8 (en) Hydroxypyrazoles for use against metabolic-related disorders
GB0307918D0 (en) Therapeutic use
IL177155A0 (en) Therapeutic combinations
GB0218526D0 (en) Combination therapy
GB0417481D0 (en) Combination therapy
GB0428180D0 (en) Combination therapy
GB0300586D0 (en) Therapeutic microfoam
GB0323258D0 (en) Therapeutic compounds
GB0424339D0 (en) Combination therapy
GB0328588D0 (en) Collimator
SI2272868T1 (en) Combination therapy for B cell disorders
GB0417558D0 (en) Novel combination therapy
GB0303289D0 (en) Combination therapy
AU2003231937A8 (en) Therapeutic methods
GB0325021D0 (en) Therapeutic combinations
GB0421438D0 (en) Combination therapy
GB0421436D0 (en) Combination therapy
GB0213383D0 (en) Therapeutic conditions
GB0316181D0 (en) Combination therapy
GB0314100D0 (en) Combination therapy
GB0329512D0 (en) Combination therapy
GB0316184D0 (en) Combination therapy
GB0316176D0 (en) Combination therapy